News

Filter

Current filters:

TransgeneOncology

Transgene, Lee’s Pharma and SillaJen confirm clinical development plan for Pexa-Vec

27-03-2014

France’s Transgene, Hong Kong-based Lee’s Pharmaceutical and South Korea’s SillaJen have unveiled…

BayerLee's PharmaceuticalNexavarOncologyPexa-VecPharmaceuticalResearchSillaJenTransgene

Sanofi and Transgene launch construction phase of joint bioproduction platform

Sanofi and Transgene launch construction phase of joint bioproduction platform

29-01-2014

French drug major Sanofi and biotech firm Transgene have launched the construction phase of the manufacturing…

BiotechnologyFranceOncologyProductionSanofiTransgene

Korea’s SillaJen to acquire Jennerex in up to $150 million deal

Korea’s SillaJen to acquire Jennerex in up to $150 million deal

27-11-2013

Privately-held South Korean firm SillaJen says it has executed a definitive merger agreement to acquire…

BiotechnologyJennerexMergers & AcquisitionsOncologyPexa-VecSillaJenTransgene

Transgene's Pexa-Vec fails in mid-stage liver cancer study

04-09-2013

French biotech firm Transgene (Euronext Paris: TNG) has revealed that TRAVERSE, a randomized Phase IIb…

BiotechnologyOncologyPexa-VecResearchTransgene

Transgene out-licenses skin cancer candidate TG1042 to Ascend Pharma

04-07-2013

French biotech firm Transgene SA (Euronext Paris: TNG) has granted Ascend Biopharmaceuticals, an emerging…

Ascend PharmaASN-002BiotechnologyLicensingOncologyTG1042Transgene

Transgene to seek partner for HCV vaccine TG4040 on strong Ph II results

09-11-2011

French biotech firm Transgene (Euronext Paris: FR0005175080) has revealed interim data showing a substantial…

BiotechnologyLicensingOncologyPharmaceuticalResearchTransgeneVaccines

Transgene in companion diagnostic deal with Beckman to select patients for TG4010

06-01-2011

French biotech firm Transgene (Euronext: TNG) yesterday signed an agreement with USA-based Beckman Coulter…

Beckman CoulterBiotechnologyLicensingNovartisOncologyPharmaceuticalTransgene

Jennerex licenses lead cancer compound to Transgene in over $116 million deal

09-09-2010

US privately-held oncology-focussed drug developer Jennerex has entered into an exclusive partnership…

JennerexLicensingOncologyPharmaceuticalTransgene

COMPANY SPOTLIGHT

Menarini

Back to top